Vectibix panitumumab: Phase III data

The open-label, international Phase III Study ‘0007 in about 377 chemorefractory mCRC patients with wild-type K-Ras (KRAS) exon 2 showed that 6 mg/kg IV Vectibix every 14 days plus best supportive ca...